The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Genzyme competitive analysis

Loading summary...

Latest patents of Genzyme opposed by its competitors

Explore Genzyme's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
EP3137497
Mar 5, 2025Aav Vectors For Retinal And Cns Gene Therapy1
EP2976359
Mar 23, 2022Methods For Treating Osteogenesis Imperfecta1
EP2970843
Sep 1, 2021High-Density Cell Banking Methods1
EP3047013
Aug 18, 2021Methods And Systems For Processing A Cell Culture1
EP3497207
Jan 6, 2021Methods For Detecting Aav2
EP3152299
Nov 20, 2019Seed Train Processes And Uses Thereof3
EP3133070
Aug 14, 2019Eliglustat (Genz 112638) As Inhibitor Of Glucosylceramide Synthase For Use In A Method Of Treating Fabry'S Or Gaucher'S Disease, The Method Comprising Adjusting The Individual Therapeutical Dose To The P-450 Metabolism Of The Patient3
EP2371361
Aug 7, 2019Methods To Mobilize Progenitor/Stem Cells7

Latest PTAB cases involving Genzyme

Discover the latest PTAB cases involving Genzyme, highlighting their recent legal challenges and patent disputes.

Last updated on: Nov 15, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Genzyme

IPR2025-01194Jun 26, 2025SAREPTA THERAPEUTICSGENZYMEInstitution Denied
IPR2025-01195Jun 26, 2025SAREPTA THERAPEUTICSGENZYMEInstitution Denied
IPR2023-01044Jun 30, 2023NOVARTIS GENE THERAPIESGENZYMETerminated-Settled
IPR2023-00608Feb 22, 2023NOVARTIS GENE THERAPIESGENZYMEInstitution Denied
IPR2023-00609Feb 22, 2023NOVARTIS GENE THERAPIESGENZYMEInstitution Denied
IPR2016-00460Jan 15, 2016GENZYMEGENENTECHTerminated-Settled
IPR2016-00383Dec 30, 2015GENZYMEGENENTECHInstitution Denied
IPR2013-00534Aug 28, 2013BIOMARIN PHARMACEUTICALGENZYME THERAPEUTIC PRODUCTS PARTNERSHIPFinal Written Decision
IPR2013-00537Aug 28, 2013BIOMARIN PHARMACEUTICALGENZYME THERAPEUTIC PRODUCTS PARTNERSHIPFinal Written Decision

Peer Comparison New

IP litigation analysis comparing Genzyme with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
GENZYME - 1925
ACCORD HEALTHCARE39 - 4 -
GENENTECH - 87 - 65
NOVARTIS GENE THERAPIES - - 4 -